PT-141 (Bremelanotide)
Boosts libido and sexual desire. A melanocortin agonist, FDA-approved as Vyleesi for female sexual dysfunction and used off-label for libido in both sexes.
PT-141 (Bremelanotide): Boosts libido and sexual desire. A melanocortin agonist, FDA-approved as Vyleesi for female sexual dysfunction and used off-label for libido in both sexes. PT-141 (FDA-approved as Vyleesi) is the libido peptide.
PT-141 (FDA-approved as Vyleesi) is the libido peptide. Different mechanism than Viagra, it works on desire, not just blood flow. Used as-needed, not daily. Nausea is the main side effect, especially the first few times.
FDA-approved drug. Most federations would not consider it disqualifying for libido use, but each federation has its own rules.
Approved as Vyleesi (Bremelanotide), 2019, for hypoactive sexual desire disorder in premenopausal women.
FDA-approved drug products containing this substance are available. Compounded versions are not FDA-approved.
Yes, Vyleesi prescribed by gynecology, primary care, sexual-medicine providers.
Who it's for
- →Users with situational or low-baseline libido
- →Couples wanting a non-PDE5-inhibitor option
- →People for whom Viagra/Cialis don't address the desire side
What to expect
- Week 1
Effect within hours of first dose. Nausea common at first.
- Week 4
Tolerance to nausea builds. Effect remains.
- Week 8
Used episodically rather than continuously.
Looking at PT-141 (Bremelanotide)? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for PT-141 (Bremelanotide).
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Melanocortin-receptor agonist (MC3R + MC4R) that acts centrally on arousal pathways in the brain rather than peripherally on blood flow (which is what PDE5 inhibitors like Viagra do). Different lever, desire vs vasodilation.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Uncontrolled hypertension
- ⚠Cardiovascular disease
- ⚠Personal history of melanoma
Bloodwork to monitor
- • Blood pressure baseline if using regularly
Common mistakes
- • Dosing too high on first use (nausea will dominate the experience)
- • Using daily instead of as-needed
- • Pairing with alcohol, amplifies nausea
What it actually is
PT-141, or bremelanotide, is an injectable that acts on melanocortin receptors in the brain to raise sexual desire. Unusually for this catalog it is an approved medicine: FDA approved it in 2019 as Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women — not for HSDD from a medical or psychiatric condition, relationship problems, or a medication effect. Clinician use of Vyleesi outside that indication is off-label; a research-chemical product is not an approved drug at all, so the term off-label does not describe it. It is a derivative of the same alpha-MSH chemistry as the tanning peptides, which is why skin darkening is on its side-effect list.
Most sexual-function drugs work on blood flow. PT-141 does not. It acts centrally, on melanocortin receptors in the hypothalamus, and the proposed target is the desire pathway rather than blood flow. The precise mechanism is not settled, and the desire-versus-mechanics distinction is a useful simplification rather than a demonstrated boundary. The same receptor family controls pigmentation and appetite, which is where the tanning and nausea come from.
Forms, and which is which
Single-use pen, fixed dose, pharmacy product with known identity and sterility. Labelled for premenopausal women with HSDD.
Verdict: The only form with assured contents.
Buyer reconstitutes and doses by eye. Identity and sterility rest on the seller.
Verdict: The common route, and the one with no quality assurance.
The original development route. The intranasal programme stalled over blood-pressure increases and the injectable was developed after it. Worth being clear: the approved injection still carries a labelled transient blood-pressure increase and heart-rate reduction, so the problem was reduced rather than removed.
Verdict: Discontinued for a safety reason, not a commercial one.
Stacks overlapping melanocortin agonists, compounding nausea, flushing and pigmentation effects with no added desire benefit.
Verdict: Two doses of the same receptor family.
What it is claimed to do, graded
The approved indication, supported by two phase 3 randomised trials (RECONNECT). The effect is statistically real and modest in size — this is not a switch.
Earlier trials in men showed erectile responses, and the male programme was not carried to approval. Real human data exists; it did not finish.
Plausible from the central mechanism and reported constantly by users. No completed trial has a male libido endpoint, and by this site's own rule that is None shown.
The opposite is documented. Transient blood pressure increases and heart rate reductions are a labelled effect, and they are why the nasal programme was stopped.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • Approved, with phase 3 evidence behind the labelled use
- • Acts on desire rather than blood flow, so it addresses a problem PDE5 inhibitors cannot
- • Used as needed rather than daily
- • Effects are not dependent on being taken with food or timed around meals
- • Nausea is the dominant side effect and is severe enough at first use that many people stop
- • Raises blood pressure transiently, which rules it out for uncontrolled hypertension
- • Causes focal hyperpigmentation, documented on the face, gums and breasts as well as in moles, and in some cases it did not resolve after stopping
- • The label caps use at 8 doses per month for a reason
- • Male use rests on erectile-response findings from a programme that was never completed, and on no trial with a libido endpoint
When to stop
- • Blood pressure rising and staying up rather than settling within hours
- • Any mole changing in size, shape or colour — get it looked at
- • Nausea severe enough to need antiemetics to tolerate
- • Chest pain or palpitations after a dose
- • Eight weeks of use without improvement in symptoms — the label says to stop
- • You suspect you may be pregnant — the label says to discontinue
- • You are approaching the 8-doses-a-month ceiling regularly
Interactions
PT-141 raises blood pressure transiently, working against them and making the net effect unpredictable.
Often assumed to worsen the nausea. The labelled randomised alcohol-interaction study did not find that, so this is a common belief rather than a documented interaction.
The Vyleesi label notes significantly reduced naltrexone exposure. In someone taking naltrexone for alcohol or opioid dependence, blunting it is a serious problem rather than a caution.
Same receptor family. Adds pigmentation and nausea without adding benefit.
Different mechanisms, and they move blood pressure in opposite directions — sildenafil lowers it, bremelanotide transiently raises it. Not additive, and not established as a combination either.
Is this for you?
- • Women with diagnosed HSDD working with a prescriber
- • People for whom blood-flow drugs have not worked because the problem is desire, not mechanics
- • Anyone reading this to understand how a central desire mechanism differs from a blood-flow one
- • You have uncontrolled hypertension or known cardiovascular disease
- • You have a personal history of melanoma or atypical moles
- • You are pregnant, nursing or trying to conceive
- • You want something daily — this is not that, and daily use is where the pigmentation shows up
The one number
Sources for the claims above
- First approval and regulatory history
- Role in hypoactive sexual desire disorder assessment and treatment
- Early development profile
Drug & supplement interactions
- ⚠Antihypertensives: PT-141 transiently elevates BP
- ⚠MAO inhibitors: theoretical melanocortin amplification
- ⚠Oral naltrexone: avoid, PT-141 slows gastric emptying and cuts naltrexone absorption ~40-60% (FDA label)
- ⚠Alcohol: compounds nausea, most users avoid alcohol within 4 hours of dose
- ⚠Maximum 1 dose per 24h; max 8 doses per month per FDA label
The Pepdex take
The bedroom peptide. It works, but the nausea on first use is no joke. Start at 0.75-1mg sub-q, NOT the labeled 1.75mg starter dose that vendors copy from the FDA-approved Vyleesi label. Anyone telling you to start at 1.75 hasn't actually run it. Time it 4-6 hours before you want the effect, not 1 hour. As-needed only, daily use blunts the response and amplifies the BP impact.
Community patterns
New to PT-141 (Bremelanotide)? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about PT-141 (Bremelanotide) or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is PT-141 (Bremelanotide)?+
Is PT-141 (Bremelanotide) FDA approved?+
Is PT-141 (Bremelanotide) legal?+
Is PT-141 (Bremelanotide) banned by WADA?+
Are you still natty after taking PT-141 (Bremelanotide)?+
Do doctors prescribe PT-141 (Bremelanotide)?+
What's the typical dose of PT-141 (Bremelanotide)?+
What are the side effects of PT-141 (Bremelanotide)?+
How long until PT-141 (Bremelanotide) starts working?+
What can you stack with PT-141 (Bremelanotide)?+
Where do people get PT-141 (Bremelanotide)?+
PT-141 (Bremelanotide) vs Kisspeptin-10, which is better?+
Common questions about PT-141 (Bremelanotide)
Head-to-head with PT-141 (Bremelanotide)
Tracked alongside PT-141 (Bremelanotide)
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.